Using EAE to better understand principles of immune function and autoimmune pathology

Frohman, 2006, Multiple sclerosis – the plaque and its pathogenesis, N Engl J Med, 354, 942, 10.1056/NEJMra052130 Meuth, 2012, Immune therapy of multiple sclerosis – future strategies, Curr Pharm Des, 18, 4489, 10.2174/138161212802502198 Cooper, 2009, Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases, J Autoimmun, 33, 197, 10.1016/j.jaut.2009.09.008 Richards, 1995, Experimental allergic encephalomyelitis in non-human primates: diffusion imaging of acute and chronic brain lesions, Mult Scler, 1, 109, 10.1177/135245859500100209 Aritake, 2010, Effects of human recombinant-interferon beta in experimental autoimmune encephalomyelitis in guinea pigs, Pharm Biol, 48, 1273, 10.3109/13880201003770135 Pearce, 2005, Historical descriptions of multiple sclerosis, Eur Neurol, 54, 49, 10.1159/000087387 McDonald, 1993, The dynamics of multiple sclerosis. The Charcot Lecture, J Neurol, 240, 28 McDonald, 2002, Multiple sclerosis in its European matrix, Mult Scler, 8, 181, 10.1191/1352458502ms821oa Wingerchuk, 2001, Multiple sclerosis: current pathophysiological concepts, Lab Invest, 81, 263, 10.1038/labinvest.3780235 McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032 Antel, 2012, Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?, Acta Neuropathol, 123, 627, 10.1007/s00401-012-0953-0 Tuohy, 1989, Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice, J Immunol, 142, 1523, 10.4049/jimmunol.142.5.1523 Tompkins, 2002, De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis, J Immunol, 168, 4173, 10.4049/jimmunol.168.8.4173 Batoulis, 2011, Experimental autoimmune encephalomyelitis – achievements and prospective advances, APMIS, 119, 819, 10.1111/j.1600-0463.2011.02794.x McRae, 1992, Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein, J Neuroimmunol, 38, 229, 10.1016/0165-5728(92)90016-E Rangachari, 2012, Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion, Nat Med, 18, 1394, 10.1038/nm.2871 Berard, 2010, Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice, Glia, 58, 434 Domingues, 2010, Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis, PLoS One, 5, e15531, 10.1371/journal.pone.0015531 Zamvil, 1985, T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination, Nature, 317, 355, 10.1038/317355a0 Zamvil, 1986, T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis, Nature, 324, 258, 10.1038/324258a0 Kennedy, 1987, Monoclonal antibody-induced inhibition of relapsing EAE in SJL/J mice correlates with inhibition of neuroantigen-specific cell-mediated immune responses, J Neuroimmunol, 16, 345, 10.1016/0165-5728(87)90110-X Whitham, 1996, Treatment of relapsing autoimmune encephalomyelitis with T cell receptor V beta-specific antibodies when proteolipid protein is the autoantigen, J Neurosci Res, 45, 104, 10.1002/(SICI)1097-4547(19960715)45:2<104::AID-JNR3>3.0.CO;2-E Kennedy, 1990, Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides, J Immunol, 144, 909, 10.4049/jimmunol.144.3.909 McRae, 1995, Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis, J Exp Med, 182, 75, 10.1084/jem.182.1.75 Whitham, 1991, Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis, J Immunol, 146, 101, 10.4049/jimmunol.146.1.101 McMahon, 2005, Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis, Nat Med, 11, 335, 10.1038/nm1202 Quintana, 2012, Antigen microarrays identify CNS-produced autoantibodies in RRMS, Neurology, 78, 532, 10.1212/WNL.0b013e318247f9f3 Miyagawa, 2010, The use of mouse models to better understand mechanisms of autoimmunity and tolerance, J Autoimmun, 35, 192, 10.1016/j.jaut.2010.06.007 Adlard, 1999, Immunoregulation of encephalitogenic MBP-NAc1-11-reactive T cells by CD4+ TCR-specific T cells involves IL-4, IL-10 and IFN-gamma, Autoimmunity, 31, 237, 10.3109/08916939908994069 Waldner, 2000, Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor, Proc Natl Acad Sci U S A, 97, 3412, 10.1073/pnas.97.7.3412 Pollinger, 2009, Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells, J Exp Med, 206, 1303, 10.1084/jem.20090299 Seong, 2004, To knockout in 129 or in C57BL/6: that is the question, Trends Genet, 20, 59, 10.1016/j.tig.2003.12.006 Mendel, 1995, A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells, Eur J Immunol, 25, 1951, 10.1002/eji.1830250723 Suen, 1997, A critical role for lymphotoxin in experimental allergic encephalomyelitis, J Exp Med, 186, 1233, 10.1084/jem.186.8.1233 Korner, 1997, Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting, J Exp Med, 186, 1585, 10.1084/jem.186.9.1585 Tran, 2000, IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines, J Immunol, 164, 2759, 10.4049/jimmunol.164.5.2759 Malipiero, 1997, Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice, Eur J Immunol, 27, 3151, 10.1002/eji.1830271211 Eugster, 1999, Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1, Eur J Immunol, 29, 626, 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A Du, 2002, Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system, J Immunol, 168, 3105, 10.4049/jimmunol.168.6.3105 Bettelli, 2004, Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis, J Exp Med, 200, 79, 10.1084/jem.20031819 Hjelmstrom, 1998, B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization, J Immunol, 161, 4480, 10.4049/jimmunol.161.9.4480 Bullard, 2007, p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis, Am J Pathol, 170, 2001, 10.2353/ajpath.2007.061016 Koh, 1992, Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice, Science, 256, 1210, 10.1126/science.256.5060.1210 Spahn, 1999, Decreased severity of myelin oligodendrocyte glycoprotein peptide 33-35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR delta chain gene, Eur J Immunol, 29, 4060, 10.1002/(SICI)1521-4141(199912)29:12<4060::AID-IMMU4060>3.0.CO;2-S Friese, 2009, Pathogenic CD8(+) T cells in multiple sclerosis, Ann Neurol, 66, 132, 10.1002/ana.21744 Crawford, 2004, High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay, Blood, 103, 4222, 10.1182/blood-2003-11-4025 Ford, 2005, Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis, Eur J Immunol, 35, 76, 10.1002/eji.200425660 Blanchard, 2008, Coping with loss of perfection in the MHC class I peptide repertoire, Curr Opin Immunol, 20, 82, 10.1016/j.coi.2007.12.004 Bettelli, 2003, Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis, J Exp Med, 197, 1073, 10.1084/jem.20021603 Pau, 2011, Optic neuritis, Eye (Lond), 25, 833, 10.1038/eye.2011.81 Litzenburger, 1998, B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice, J Exp Med, 188, 169, 10.1084/jem.188.1.169 Krishnamoorthy, 2006, Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation, J Clin Invest, 116, 2385, 10.1172/JCI28330 Bettelli, 2006, Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice, J Clin Invest, 116, 2393, 10.1172/JCI28334 Misu, 2002, Pure optic-spinal form of multiple sclerosis in Japan, Brain, 125, 2460, 10.1093/brain/awf260 Jäger, 2009, Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes, J Immunol, 183, 7169, 10.4049/jimmunol.0901906 Encinas, 1999, QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2, Nat Genet, 21, 158, 10.1038/5941 Degenhardt, 2009, Clinical prognostic factors in multiple sclerosis: a natural history review, Nat Rev Neurol, 5, 672, 10.1038/nrneurol.2009.178 Anderson, 2012, A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells, J Immunol, 188, 2084, 10.4049/jimmunol.1102186 Mosmann, 1986, Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, J Immunol, 136, 2348, 10.4049/jimmunol.136.7.2348 Cherwinski, 1987, Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies, J Exp Med, 166, 1229, 10.1084/jem.166.5.1229 de Waal Malefyt, 1993, Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10, J Immunol, 151, 6370, 10.4049/jimmunol.151.11.6370 Lucey, 1999, Evolution of the type-1 (Th1)-type-2 (Th2) cytokine paradigm, Infect Dis Clin North Am, 13, 1, 10.1016/S0891-5520(05)70039-8 Adorini, 1996, Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases?, Autoimmunity, 23, 53, 10.3109/08916939608995329 Ferber, 1996, Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE), J Immunol, 156, 5, 10.4049/jimmunol.156.1.5 Krakowski, 1996, Interferon-gamma confers resistance to experimental allergic encephalomyelitis, Eur J Immunol, 26, 1641, 10.1002/eji.1830260735 Chu, 2000, Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis, J Exp Med, 192, 123, 10.1084/jem.192.1.123 Becher, 2002, Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12, J Clin Invest, 110, 493, 10.1172/JCI0215751 Oppmann, 2000, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, 13, 715, 10.1016/S1074-7613(00)00070-4 Gran, 2002, IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination, J Immunol, 169, 7104, 10.4049/jimmunol.169.12.7104 Cua, 2003, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, 421, 744, 10.1038/nature01355 Zhang, 2003, Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system, J Immunol, 170, 2153, 10.4049/jimmunol.170.4.2153 Park, 2005, A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nat Immunol, 6, 1133, 10.1038/ni1261 Langrish, 2005, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J Exp Med, 201, 233, 10.1084/jem.20041257 Parham, 2002, A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R, J Immunol, 168, 5699, 10.4049/jimmunol.168.11.5699 Bettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038/nature04753 Mangan, 2006, Transforming growth factor-beta induces development of the T(H)17 lineage, Nature, 441, 231, 10.1038/nature04754 Veldhoen, 2006, Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease, Nat Immunol, 7, 1151, 10.1038/ni1391 Nurieva, 2007, Essential autocrine regulation by IL-21 in the generation of inflammatory T cells, Nature, 448, 480, 10.1038/nature05969 Korn, 2007, IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells, Nature, 448, 484, 10.1038/nature05970 Bettelli, 2007, Th17: the third member of the effector T cell trilogy, Curr Opin Immunol, 19, 652, 10.1016/j.coi.2007.07.020 Fitch, 2007, Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines, Curr Rheumatol Rep, 9, 461, 10.1007/s11926-007-0075-1 Scheinecker, 2011, Rheumatoid arthritis in 2010: from the gut to the joint, Nat Rev Rheumatol, 7, 73, 10.1038/nrrheum.2010.226 Shao, 2012, Th17 cells in type 1 diabetes, Cell Immunol, 280, 16, 10.1016/j.cellimm.2012.11.001 Fletcher, 2010, T cells in multiple sclerosis and experimental autoimmune encephalomyelitis, Clin Exp Immunol, 162, 1, 10.1111/j.1365-2249.2010.04143.x Maddur, 2012, Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies, Am J Pathol, 181, 8, 10.1016/j.ajpath.2012.03.044 Yeilding, 2012, Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives–an update, Ann N Y Acad Sci, 1263, 1, 10.1111/j.1749-6632.2012.06670.x Rich, 2013, Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study, Br J Dermatol, 168, 402, 10.1111/bjd.12070 Miossec, 2012, Targeting IL-17 and TH17 cells in chronic inflammation, Nat Rev Drug Discov, 11, 763, 10.1038/nrd3794 Yosef, 2013, Dynamic regulatory network controlling TH17 cell differentiation, Nature, 496, 461, 10.1038/nature11981 Wu, 2013, Induction of pathogenic T17 cells by inducible salt-sensing kinase SGK1, Nature, 496, 513, 10.1038/nature11984 Lang, 2006, (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms, Physiol Rev, 86, 1151, 10.1152/physrev.00050.2005 Kleinewietfeld, 2013, Sodium chloride drives autoimmune disease by the induction of pathogenic T17 cells, Nature, 496, 518, 10.1038/nature11868 Pentcheva-Hoang, 2009, Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections, Immunol Rev, 229, 67, 10.1111/j.1600-065X.2009.00763.x McCoy, 1999, The role of CTLA-4 in the regulation of T cell immune responses, Immunol Cell Biol, 77, 1, 10.1046/j.1440-1711.1999.00795.x Karandikar, 1996, CTLA-4: a negative regulator of autoimmune disease, J Exp Med, 184, 783, 10.1084/jem.184.2.783 Hurwitz, 1997, Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis, J Neuroimmunol, 73, 57, 10.1016/S0165-5728(96)00168-3 Perrin, 1996, CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis, J Immunol, 157, 1333, 10.4049/jimmunol.157.4.1333 Hurwitz, 2002, Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice, Proc Natl Acad Sci U S A, 99, 3013, 10.1073/pnas.042684699 Francisco, 2010, The PD-1 pathway in tolerance and autoimmunity, Immunol Rev, 236, 219, 10.1111/j.1600-065X.2010.00923.x Salama, 2003, Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis, J Exp Med, 198, 71, 10.1084/jem.20022119 Zhu, 2006, Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis, J Immunol, 176, 3480, 10.4049/jimmunol.176.6.3480 Carter, 2007, PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis, J Neuroimmunol, 182, 124, 10.1016/j.jneuroim.2006.10.006 Monney, 2002, Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease, Nature, 415, 536, 10.1038/415536a Sabatos, 2003, Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance, Nat Immunol, 4, 1102, 10.1038/ni988 Sanchez-Fueyo, 2003, Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance, Nat Immunol, 4, 1093, 10.1038/ni987 Zhu, 2005, The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity, Nat Immunol, 6, 1245, 10.1038/ni1271 Koguchi, 2006, Dysregulated T cell expression of TIM3 in multiple sclerosis, J Exp Med, 203, 1413, 10.1084/jem.20060210 Yang, 2008, Lack of TIM-3 immunoregulation in multiple sclerosis, J Immunol, 180, 4409, 10.4049/jimmunol.180.7.4409 Jones, 2008, Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection, J Exp Med, 205, 2763, 10.1084/jem.20081398 Golden-Mason, 2009, Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells, J Virol, 83, 9122, 10.1128/JVI.00639-09 Sakuishi, 2010, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, J Exp Med, 207, 2187, 10.1084/jem.20100643 Zhou, 2011, Co-expression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia, Blood, 10.1182/blood-2010-10-310425 Wherry, 2011, T cell exhaustion, Nat Immunol, 12, 492, 10.1038/ni.2035 Gershwin, 2011, Chella David: a lifetime contribution in translational immunology, J Autoimmun, 37, 59, 10.1016/j.jaut.2011.05.011 Jamin, 2012, Pierre Youinou: when intuition and determination meet autoimmunity, J Autoimmun, 39, 117, 10.1016/j.jaut.2012.05.004 Tzioufas, 2012, Pathogenesis of Sjogren's syndrome: what we know and what we should learn, J Autoimmun, 39, 4, 10.1016/j.jaut.2012.01.002